RECENT ANALYSIS
Ways and Means Committee Examines H.R. 3, the Lower Drug Costs Now Act, and Education and Labor Committee Favorably Reports AINS to H.R. 3
The House Ways and Means Committee convened a hearing to discuss H.R. 3, the Lower Drug Costs Now Act (summary). The Ways and Means Committee is the third House Committee to examine the bill. Witnesses testified about the difficulties both privately insured beneficiaries and Medicare beneficiaries face in affording their medications and how H.R. 3 savings could be reinvested into… (Slifer, 10/17/19) #Insurance Reform, #Medicare Part D, #Prescription Drugs
Subcommittee Examines E-Cigarettes and Youth Tobacco Epidemic
The House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies convened a hearing to examine the Centers for Disease Control and Prevention’s (CDC) ongoing investigation of lung injury associated with e-cigarette use, discuss the youth tobacco epidemic, and identify public policy remedies. Overall, members from both parties agreed that efforts should be made to prevent children… (Llamas, 10/16/19) #Food and Drug Administration, #Pediatrics, #Public Health
Initial Cost Estimates of H.R. 3; Price Negotiation, Inflation Rebates Analyzed
The Congressional Budget Office (CBO) released a preliminary cost estimate of title I of the Lower Drug Costs Now Act of 2019 (H.R. 3) regarding price negotiation of certain prescription drugs in Medicare Part D. CBO estimates that enacting title I would reduce federal spending for Medicare by $345 billion over the 2023-2029 period. A summary follows below. Title I… (Llamas) #Insurance Reform, #Medicare Part D, #Prescription Drugs